Physician profile
Michael S Silvey
NPI 1578747994
$123,989.44
in general payments reported to CMS, 2019-2025
13 companies · $11K in 2025
The $11K reported for 2025 was more than what 86% of Pediatric Hematology-Oncology providers received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $36K · 2020: $16K · 2021: $10K · 2022: $3,408 · 2023: $21K · 2024: $26K · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $46K · Travel and Lodging: $4,470 · Food and Beverage: $3,922 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,760.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $46,088.00 |
| Travel and Lodging | $4,470.31 |
| Food and Beverage | $3,922.11 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,760.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $84,630.50 | 2019-2025 | Hemlibra |
| Genzyme Corporation | $29,549.18 | 2019-2025 | |
| Hema Biologics, LLC | $6,000.00 | 2023 | Sevenfact |
| Bioverativ Therapeutics INC. | $2,958.00 | 2020 | |
| Genentech, INC. | $333.02 | 2021-2024 | Hemlibra |
| Novo Nordisk INC | $158.99 | 2023-2025 | |
| Octapharma USA, INC. | $107.34 | 2025 | Balfaxar |
| Shire North American Group INC | $80.94 | 2019 | |
| Kedrion Biopharma INC. | $73.27 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $57.77 | 2022-2025 | Vonvendi |
| Pfizer INC. | $21.00 | 2025 | |
| Novartis Pharmaceuticals Corporation | $19.43 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Silvey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.